Cardioprotection thread, page-649

It is always quite funny reading your posts.

Show me a single study that has compared Annamycin DIRECTLY against Doxorubicin in cancer patients. They won't run that trial because it lacks efficacy, but you don't have to be a genius to work that out. The phase III registrational trial will have to go up against SoC.



There's a new anthracycline being developed



"Heavily pre-treated patients"

Actually first or second line patients. And the CR rate is definitely higher than 3%, so you are improving.



Reon, the likelihood chance that Annamycin is a viable commercial product is substantially less than Bisantrene in combination with Doxorubicin. It doesn't take a genius to work out that anthracyclines are approved across multiple indications. This opens the use case for Bisantrene, a universal CPACS drug, significantly more than it does an old anthracycline-like compound, Annamycin, that has to compete against the #1 ranked most essential drug in the world (Doxorubicin) that has been used for over half a century.




If Bisantrene is able to provide meaningful cardioprotection in combination with Doxorubicin, then the cumulative dosing of Doxorubicin can increase. This increases the use case of the already number 1 most essential anti-cancer agent in the world. You quite literally have oncologists from 82 countries all saying the same thing able to dose the number 1 drug in the world while achieving better efficacy, more freedom with cumulative dosing, and cardioprotection.

It is not the only potential use for Bisantrene in patients, but if you want to prove CPACS in any drug, you do it with Dox.